| Market Cap | 11.75M | P/E | - | EPS this Y | 51.30% | Ern Qtrly Grth | - |
| Income | -2.13M | Forward P/E | -0.73 | EPS next Y | -15.80% | 50D Avg Chg | -29.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -87.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -96.00% |
| Recommedations | 2.00 | Quick Ratio | 0.01 | Shares Outstanding | 15.08M | 52W Low Chg | 24.00% |
| Insider Own | 46.87% | ROA | -3.15% | Shares Float | 6.08M | Beta | - |
| Inst Own | 43.85% | ROE | - | Shares Shorted/Prior | 58K/185K | Price | 0.50 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 5,165,440 | Target Price | 9.00 |
| Oper. Margin | - | Earnings Date | - | Volume | 759,413 | Change | -3.44% |
Revelation Biosciences, Inc., a clinical -stage biopharmaceutical company, focuses on the development or commercialization of innate immune system therapeutics and diagnostics. The company's lead therapeutic candidate is REVTx-99, an anti -viral nasal drop for the prevention or treatment of respiratory viral infections, as well as for the prevention or treatment of nasal congestion due to allergies or chronic rhinosinusitis. Its lead diagnostic is the REVDx -501, a rapid test kit to detect various respiratory viral infections. The company also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination. Revelation Biosciences, Inc. was founded in 2019 and is headquartered in San Diego, California.
| Roth Capital | Buy | Feb 17, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| TIDMARSH GEORGE F | Director Director | Feb 25 | Buy | 1.60 | 20,000 | 32,000 | 467,156 | 02/28/22 |
| TIDMARSH GEORGE F | Director Director | Feb 08 | Buy | 2.55 | 31,000 | 79,050 | 447,156 | 02/10/22 |
| TIDMARSH GEORGE F | Director Director | Feb 04 | Buy | 2.46 | 50,000 | 123,000 | 1,523,335 | 02/08/22 |